2017 American Transplant Congress
Increasing Liver Transplant Waitlist Dropout for Hepatocellular Carcinoma with Widening Geographical Disparities: Implications for Organ Allocation.
Given the increasing incidence of hepatocellular carcinoma (HCC) and regional differences in liver transplant (LT) rates for HCC, we used the United Network for Organ…2017 American Transplant Congress
Infectious Complications Following Hepatectomy for Pediatric Hepatoblastoma.
Pediatric Surgery, Baylor College of Medicine, Houston, TX
Purpose: To examine if patients with hepatoblastoma (HB) treated with both immunosuppression and chemotherapy have different rates of infection post-operatively than those treated with chemotherapy…2017 American Transplant Congress
Long Wait Time Regions for Liver Transplantation for HCC Have a Higher Cumulative Incidence of Death.
Abdominal Transplantation, University of Southern California, Los Angeles, CA
Purpose: To determine the effect of regional variability in wait timeon survival of patients with hepatocellular carcinoma(HCC) listed for deceased donor liver transplantation(DDLT).Methods: Patients age>18…2017 American Transplant Congress
Malignancy in Patients Undergoing Simultaneous Heart-Liver and Heart-Kidney Transplant.
University of Pennsylvania, Philadelphia, PA
Purpose: While evidence suggests that patients undergoing simultaneous heart-liver and heart-kidney transplant may have improved immunoprotection from allograft rejection versus patients undergoing heart transplant only,…2016 American Transplant Congress
Pre-Transplant Prostate Cancer in Lung Transplant Recipients and Impact on Post-Transplant Morbidity and Mortality.
Respiratory Institute, Cleveland Clinic, Cleveland, OH.
PurposeAssess the impact of pre-transplant prostate cancer on mortality after lung transplant and the incidence of recurrence of prostate cancer after transplant.MethodsThe electronic medical records…2016 American Transplant Congress
Recipient Outcomes in U.S. Cases of Post-Donation Living Donor Malignancy.
Background: Under current OPTN policy, living donors (LD) are required to be followed for two years (yrs) post-donation. Cases of malignancy in LD post-donation can…2016 American Transplant Congress
Thorough Pre-Transplant Evaluation and Appropriate Case Selection Is the Mainstay for Better Survival in Recipients with Malignancy.
IntroductionMalignancy has become one of the three major causes of death after transplantation in the past decade and is thus increasingly important in all organ…2016 American Transplant Congress
C3 Glomerulopathy Secondary to Complement Factor H Inhibition by Monoclonal Kappa Light Chains.
Background: Monoclonal gammopathy of renal significance (MGRS) implies a causal relationship between clonal B cell proliferation and renal disease and is associated with high morbidity…2016 American Transplant Congress
Age Adapted Immunosuppression for Elderly Kidney Allograft Recipients: Balancing Risks for Cancer versus Rejection.
Introduction Cancer is a growing cause of morbidity and mortality after kidney transplantation, driven by immunosuppression. Age is one of the strongest risk factors for…2016 American Transplant Congress
A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
Intro: The OPTN DTAC evaluates potential donor derived transmission events (PDDTE), including infections & malignancies, to assess for donor transmitted events.Methods: Reports of unexpected PDDTE…
- « Previous Page
- 1
- …
- 14
- 15
- 16
- 17
- 18
- …
- 20
- Next Page »